Gilead Sciences Valuation
Is GILD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Por debajo del valor justo
Muy por debajo del valor justo
Price-To-Earnings vs. similares
Price-To-Earnings vs. Industria
PM vs. Ratio Justo
Pronóstico de los analistas
Share Price vs Fair Value
What is the Fair Price of GILD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Por debajo del valor justo: GILD ($65.55) cotiza por debajo de nuestra estimación de valor razonable ($141.62)
Muy por debajo del valor justo: GILD cotiza por debajo de su valor razonable en más de un 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GILD?
Other financial metrics that can be useful for relative valuation.
| What is GILD's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$86.56b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.8x |
| Enterprise Value/EBITDA | 8.2x |
| PEG Ratio | 2.3x |
Price to Earnings Ratio vs Peers
How does GILD's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 28.1x | ||
REGN Regeneron Pharmaceuticals | 25.7x | 10.9% | US$100.9b |
CSL CSL | 36.3x | 14.8% | AU$135.3b |
VRTX Vertex Pharmaceuticals | 28.9x | 11.2% | US$104.5b |
AMGN Amgen | 21.6x | 9.1% | US$144.3b |
GILD Gilead Sciences | 15.3x | 6.5% | US$86.6b |
Price-To-Earnings vs. similares: GILD es un buen valor basado en su Ratio Price-To-Earnings (17x) comparado con la media de sus homólogos (26.8x).
Price to Earnings Ratio vs Industry
How does GILD's PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Earnings vs. Industria: GILD es un buen valor basado en su Ratio Price-To-Earnings (17x) comparado con la media del sector Global Biotechs (34.5x).
Price to Earnings Ratio vs Fair Ratio
What is GILD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 15.3x |
| Fair PE Ratio | n/a |
PM vs. Ratio Justo: Datos insuficientes para calcular GILD's Price-To-Earnings Fair Ratio para el análisis de valoración.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$65.55 | US$86.37 +31.8% | 12.6% | US$121.00 | US$69.00 | n/a | 26 |
| Apr ’25 | US$65.55 | US$86.45 +31.9% | 12.6% | US$121.00 | US$69.00 | n/a | 26 |
| Mar ’25 | US$65.55 | US$87.86 +34.0% | 12.5% | US$121.00 | US$69.00 | n/a | 27 |
| Feb ’25 | US$65.55 | US$89.97 +37.2% | 11.9% | US$116.00 | US$69.00 | n/a | 27 |
| Jan ’25 | US$65.55 | US$90.15 +37.5% | 11.9% | US$116.00 | US$69.00 | n/a | 27 |
| Dec ’24 | US$65.55 | US$90.39 +37.9% | 11.7% | US$116.00 | US$71.00 | n/a | 27 |
| Nov ’24 | US$65.55 | US$90.95 +38.7% | 11.2% | US$116.00 | US$71.00 | n/a | 26 |
| Oct ’24 | US$65.55 | US$91.33 +39.3% | 10.8% | US$116.00 | US$71.00 | n/a | 26 |
| Sep ’24 | US$65.55 | US$91.75 +40.0% | 10.3% | US$116.00 | US$80.00 | n/a | 24 |
| Aug ’24 | US$65.55 | US$91.64 +39.8% | 10.1% | US$115.00 | US$77.00 | n/a | 25 |
| Jul ’24 | US$65.55 | US$92.60 +41.3% | 9.8% | US$115.00 | US$77.00 | n/a | 25 |
| Jun ’24 | US$65.55 | US$92.59 +41.2% | 9.8% | US$115.00 | US$77.00 | n/a | 25 |
| May ’24 | US$65.55 | US$92.56 +41.2% | 8.8% | US$115.00 | US$80.00 | n/a | 25 |
| Apr ’24 | US$65.55 | US$91.23 +39.2% | 9.7% | US$115.00 | US$77.00 | US$65.55 | 22 |
| Mar ’24 | US$65.55 | US$92.17 +40.6% | 10.4% | US$115.00 | US$77.00 | US$65.55 | 23 |
| Feb ’24 | US$65.55 | US$87.71 +33.8% | 12.4% | US$111.00 | US$63.00 | US$65.55 | 24 |
| Jan ’24 | US$65.55 | US$84.79 +29.4% | 13.0% | US$105.00 | US$63.00 | US$65.55 | 24 |
| Dec ’23 | US$65.55 | US$82.25 +25.5% | 12.2% | US$105.00 | US$63.00 | US$65.55 | 24 |
| Nov ’23 | US$65.55 | US$78.61 +19.9% | 12.9% | US$98.00 | US$63.00 | US$65.55 | 24 |
| Oct ’23 | US$65.55 | US$71.20 +8.6% | 11.1% | US$90.00 | US$56.00 | US$65.55 | 23 |
| Sep ’23 | US$65.55 | US$70.47 +7.5% | 11.3% | US$90.00 | US$56.00 | US$65.55 | 23 |
| Aug ’23 | US$65.55 | US$70.17 +7.1% | 11.3% | US$90.00 | US$56.00 | US$65.55 | 23 |
| Jul ’23 | US$65.55 | US$69.65 +6.3% | 11.3% | US$90.00 | US$56.00 | US$65.55 | 23 |
| Jun ’23 | US$65.55 | US$70.18 +7.1% | 11.2% | US$90.00 | US$56.00 | US$65.55 | 25 |
| May ’23 | US$65.55 | US$70.60 +7.7% | 11.3% | US$90.00 | US$56.00 | US$65.55 | 24 |
| Apr ’23 | US$65.55 | US$72.19 +10.1% | 11.4% | US$90.00 | US$56.00 | US$65.55 | 24 |
Pronóstico de los analistas: El precio objetivo es más de un 20% superior al precio actual de la acción y los analistas están dentro de un rango de acuerdo estadísticamente seguro.